AU2015333728B2 - Peptide-based methods for treating pancreatic cancer - Google Patents

Peptide-based methods for treating pancreatic cancer Download PDF

Info

Publication number
AU2015333728B2
AU2015333728B2 AU2015333728A AU2015333728A AU2015333728B2 AU 2015333728 B2 AU2015333728 B2 AU 2015333728B2 AU 2015333728 A AU2015333728 A AU 2015333728A AU 2015333728 A AU2015333728 A AU 2015333728A AU 2015333728 B2 AU2015333728 B2 AU 2015333728B2
Authority
AU
Australia
Prior art keywords
peptide
phe
lys
arg
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015333728A
Other languages
English (en)
Other versions
AU2015333728A1 (en
Inventor
Jesse M. Jaynes
Henry W. Lopez
George R. Martin
Udo RUDLOFF
Clayton Yates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riptide Bioscience Inc
US Department of Health and Human Services
Original Assignee
Usa As Represented By Secretary
Riptide Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usa As Represented By Secretary, Riptide Bioscience Inc filed Critical Usa As Represented By Secretary
Publication of AU2015333728A1 publication Critical patent/AU2015333728A1/en
Application granted granted Critical
Publication of AU2015333728B2 publication Critical patent/AU2015333728B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/10—Bryophyta (mosses)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
AU2015333728A 2014-10-14 2015-10-13 Peptide-based methods for treating pancreatic cancer Ceased AU2015333728B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462063909P 2014-10-14 2014-10-14
US62/063,909 2014-10-14
PCT/US2015/055305 WO2016061087A1 (en) 2014-10-14 2015-10-13 Peptide-based methods for treating pancreatic cancer

Publications (2)

Publication Number Publication Date
AU2015333728A1 AU2015333728A1 (en) 2017-05-18
AU2015333728B2 true AU2015333728B2 (en) 2020-07-30

Family

ID=54365375

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015333728A Ceased AU2015333728B2 (en) 2014-10-14 2015-10-13 Peptide-based methods for treating pancreatic cancer
AU2015333678A Active AU2015333678B2 (en) 2014-10-14 2015-10-13 Peptides having anti-inflammatory properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2015333678A Active AU2015333678B2 (en) 2014-10-14 2015-10-13 Peptides having anti-inflammatory properties

Country Status (10)

Country Link
US (5) US9492499B2 (OSRAM)
EP (2) EP3206703B1 (OSRAM)
JP (3) JP6613312B2 (OSRAM)
KR (3) KR102478073B1 (OSRAM)
CN (2) CN107580502B (OSRAM)
AU (2) AU2015333728B2 (OSRAM)
BR (1) BR112017007543A2 (OSRAM)
CA (2) CA2963478A1 (OSRAM)
WO (2) WO2016061087A1 (OSRAM)
ZA (1) ZA201702537B (OSRAM)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014100615A1 (en) 2012-12-20 2014-06-26 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
WO2017149012A1 (en) * 2016-03-02 2017-09-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Peptides and uses thereof for reducing cd95-mediated cell motility
SG11201807770RA (en) * 2016-03-24 2018-10-30 Nantcell Inc Sequence arrangements and sequences for neoepitope presentation
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
EP3454884B1 (en) 2016-05-10 2023-07-12 Sorbonne Université Agents that activate cd47 and their use in the treatment of inflammation
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN109789190A (zh) 2016-06-30 2019-05-21 河谷控股Ip有限责任公司 Nant癌症疫苗
CN106432014B (zh) * 2016-09-05 2019-08-16 中国医学科学院放射医学研究所 胺基硫醇类化合物及其制备方法和其在辐射防护中的应用
US10799555B2 (en) 2016-09-15 2020-10-13 Leidos, Inc. PD-1 peptide inhibitors
TWI808063B (zh) * 2016-11-09 2023-07-11 國立臺灣大學 治療或預防癌症的方法
US20190358263A1 (en) * 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
CA3051481A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
AU2018258119B2 (en) 2017-04-24 2021-04-01 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
ES3041991T3 (en) 2017-05-25 2025-11-17 Leidos Inc Pd-1 and ctla-4 dual inhibitor peptides
EP3687559B1 (en) 2017-09-29 2025-11-12 Sanford Burnham Prebys Medical Discovery Institute Compositions that target tumor-associated macrophages and methods of use therefor
CN109745324A (zh) * 2017-11-06 2019-05-14 中国科学院上海生命科学研究院 非经典NF-kB通路的小分子抑制剂及其应用
JP7549303B2 (ja) 2018-01-22 2024-09-11 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞の使用方法
CN111936518A (zh) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） 对fl-ple标记的肿瘤表现出最佳的t细胞功能的荧光素特异性car
JP7273421B2 (ja) 2018-02-21 2023-05-15 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
CN112105382A (zh) 2018-02-23 2020-12-18 恩多塞特公司 用于car t细胞疗法的顺序方法
AU2018410849B2 (en) 2018-02-27 2025-02-27 Leidos, Inc. PD-1 peptide inhibitors
US11823773B2 (en) 2018-04-13 2023-11-21 Nant Holdings Ip, Llc Nant cancer vaccine strategies
EP3810278A1 (en) * 2018-06-20 2021-04-28 Universidade de Coimbra (3s)- and (3r)-6,7-bis(hydroxymethyl)-1h,3h-pyrrolo[1,2-c]thiazoles as p53 activators
BR112021005464A2 (pt) * 2018-08-15 2021-06-29 The Regents Of The University Of California inibição de il-10 para vacinas e imunoterapia
US12385903B2 (en) 2018-08-27 2025-08-12 Nantbio, Inc. RP182 compositions and methods
JP7766489B2 (ja) * 2018-08-29 2025-11-10 リップタイド バイオサイエンス インコーポレイテッド 免疫調節特性を有するペプチド
US20220143130A1 (en) * 2018-08-29 2022-05-12 Riptide Bioscience, Inc. Peptides Having Immunomodulatory Properties
US10413584B1 (en) 2018-08-29 2019-09-17 Riptide Bioscience, Inc. Peptides having immunomodulatory properties
CN110960679A (zh) * 2018-09-28 2020-04-07 江苏康缘药业股份有限公司 一种抗肿瘤的药物组合物及其应用
US20220053773A1 (en) * 2018-10-01 2022-02-24 Innate Immunity LLC Compositions and methods for the treatment of pathogenic infections in plants
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US10548944B1 (en) 2018-10-19 2020-02-04 Riptide Bioscience, Inc. Antimicrobial peptides and methods of using the same
US12465640B2 (en) 2019-02-25 2025-11-11 The University Of Chicago Methods and compositions for treating inflammatory and autoimmune conditions with ECM-affinity peptides linked to anti-inflammatory agents
CN114207117A (zh) * 2019-04-12 2022-03-18 激流生物科学有限公司 用于调节巨噬细胞活性的方法
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
WO2020263463A1 (en) 2019-06-28 2020-12-30 Immunitybio, Inc. Pharmaceutical compositions to enhance phagocytosis without inflammation
JP2023507610A (ja) 2019-12-19 2023-02-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２０６モジュレーター、その使用、および調製方法
CN111116713B (zh) * 2020-01-07 2023-06-23 郑州大学 Sirpa蛋白亲和环肽及其应用
CN115734970A (zh) * 2020-03-31 2023-03-03 因内特免疫有限公司 用于治疗火疫病的重组肽
US11338040B2 (en) 2020-06-04 2022-05-24 Leidos, Inc. Immunomodulatory compounds
WO2022034523A1 (en) 2020-08-13 2022-02-17 Immunitybio, Inc. Phagocytosis-inducing compounds and methods of use
CA3198203A1 (en) 2020-10-12 2022-04-21 Leidos, Inc. Immunomodulatory peptides
US20240293500A1 (en) * 2021-06-28 2024-09-05 Korea University Research And Business Foundation Peptide having anticancer activity, and use thereof
CN115607674B (zh) * 2021-07-15 2023-09-19 深圳开悦生命科技有限公司 Rna解旋酶dhx33抑制剂在制备用于治疗胰腺癌的药物中的应用
WO2023080578A1 (ko) * 2021-11-05 2023-05-11 주식회사 레메디 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
WO2023097111A2 (en) * 2021-11-29 2023-06-01 Riptide Bioscience, Inc. Methods and compositions for treating calcinosis associated conditions
EP4277645A1 (en) * 2021-12-16 2023-11-22 Ramakrishna Reddy Isanaka A stable anti-angiogenic and anti-inflammatory pharmaceutical formulation and pharmaceutical combination for treatment and prevention of psoriasis
WO2024102993A1 (en) * 2022-11-10 2024-05-16 Research Foundation Of The City University Of New York Cationically-enframed high density aromatic peptides
CN115838395A (zh) * 2022-11-15 2023-03-24 西北农林科技大学 具有可溶性环氧化物水解酶抑制作用的活性肽及其应用
CN116768970A (zh) * 2023-05-19 2023-09-19 重庆师范大学 抗氧化多肽、制备方法及其应用
CN117143183B (zh) * 2023-08-25 2024-08-16 广州益养生物科技有限公司 一种三肽、三肽盐或衍生物及其应用
WO2025093952A1 (en) * 2023-10-30 2025-05-08 Ramakrishna Reddy Isanaka Peptide with anti-inflammatory and anti-microbial activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383770B1 (en) 1987-07-06 1995-09-13 Louisiana State University and Agricultural and Mechanical College Inhibition of eucaryotic pathogens and neoplasms with lytic peptides
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
ATE189231T1 (de) 1989-04-10 2000-02-15 Helix Biomedix Inc Lytische peptide, verwendung als wachstumsfördernde mittel und für infektionen und krebs
WO1993003749A1 (en) * 1991-08-21 1993-03-04 Board Of Regents, The University Of Texas System Methods and compositions for modulating g protein action
US5955573A (en) * 1993-06-04 1999-09-21 Demegen, Inc. Ubiquitin-lytic peptide fusion gene constructs, protein products deriving therefrom, and methods of making and using same
US5561107A (en) * 1993-06-04 1996-10-01 Demeter Biotechnologies, Ltd. Method of enhancing wound healing by stimulating fibroblast and keratinocyte growth in vivo, utilizing amphipathic peptides
WO1995013085A1 (en) 1993-11-08 1995-05-18 Demeter Biotechnologies Ltd. Methylated lysine-rich lytic peptides and method of making same by reductive alkylation
IL114697A0 (en) * 1994-07-22 1995-11-27 Demeter Biotech Ltd Polypeptides comprising ubiquitin-lytic peptide fusion protein products deriving therefrom their preparation and use
JP2001501620A (ja) * 1996-10-04 2001-02-06 デメジェン インコーポレイテッド 免疫不全ウイルス感染の治療方法
DE19711831C2 (de) 1997-03-21 2000-07-13 Daimler Chrysler Ag Schmelzinfiltrierte faserverstärkte Verbundkeramik und Verfahren zur Herstellung einer solchen
AU6587998A (en) * 1997-03-27 1998-10-20 Demeter Biotechnologies, Ltd. Ligand/lytic peptide compositions and methods of use
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
CA2378480A1 (en) * 1999-08-09 2001-02-15 Tripep Ab Pharmaceutical compositions containing tripeptides
EP2105141B1 (en) 2001-03-28 2012-08-08 Helix Biomedix, Inc. Short bioactive peptides and methods for their use
US7091185B2 (en) * 2003-02-24 2006-08-15 Dow Global Technologies Inc. Periodic antimicrobial peptides
GB0326393D0 (en) 2003-11-12 2003-12-17 Ares Trading Sa Cytokine antagonist molecules
US7288622B1 (en) * 2006-09-19 2007-10-30 Issar Pharmaceuticals Pvt Ltd Composition for treatment of burns and wounds
US7803755B2 (en) 2006-12-21 2010-09-28 Jesse Jaynes Molecules for the treatment and prevention of fungal diseases
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101485885B (zh) * 2009-01-09 2012-06-27 中国科学院广州生物医药与健康研究院 蛋白磷酸酯酶PPM1E作为疾病的治疗靶标及其应用和siRNA
GB0916576D0 (en) * 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
WO2012050892A2 (en) * 2010-09-29 2012-04-19 Esperance Pharmaceuticals, Inc. Methods for stimulating, increasing or enhancing killing of a cell that expresses luteinizing hormone releasing hormone (lhrh) receptors
US8734775B2 (en) 2011-08-26 2014-05-27 University Of Pittsburgh Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments
US9487560B2 (en) 2013-05-02 2016-11-08 ISSAR Pharmaceuticals Ltd Angiogenic active lytic peptides
JP6613312B2 (ja) * 2014-10-14 2019-11-27 ジ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンティッド バイ ザ セクレタリー，デパートメント オブ ヘルス アンド ヒューマン サービシズ 膵臓癌を処置するためのペプチドをベースとする方法
US9737584B2 (en) * 2015-08-11 2017-08-22 Issar Pharmaceuticals Composition for the treatment of burns, diabetic wounds, other types of wounds and subsequently greatly reduced scarring

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A. H. KO: "FOLFIRINOX: A Small Step or a Great Leap Forward?", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 29, no. 28, 1 October 2011 (2011-10-01), US, pages 3727 - 3729, XP055230684, ISSN: 0732-183X, DOI: 10.1200/JCO.2011.37.3464 *

Also Published As

Publication number Publication date
AU2015333678B2 (en) 2020-05-14
US20170252396A1 (en) 2017-09-07
AU2015333728A1 (en) 2017-05-18
JP7023709B2 (ja) 2022-02-22
KR20230004907A (ko) 2023-01-06
US20210077566A1 (en) 2021-03-18
EP3206704B1 (en) 2022-04-20
US20160101150A1 (en) 2016-04-14
BR112017007543A2 (pt) 2017-12-19
JP2020180149A (ja) 2020-11-05
JP2018503668A (ja) 2018-02-08
US10149886B2 (en) 2018-12-11
CA2963478A1 (en) 2016-04-21
JP6613312B2 (ja) 2019-11-27
KR20170070152A (ko) 2017-06-21
CN107580502B (zh) 2020-10-30
KR20170078689A (ko) 2017-07-07
US9492499B2 (en) 2016-11-15
EP3206704A4 (en) 2018-10-17
AU2015333678A1 (en) 2017-04-27
CA2964361A1 (en) 2016-04-21
ZA201702537B (en) 2020-10-28
NZ730865A (en) 2024-02-23
US20190046601A1 (en) 2019-02-14
JP2017537141A (ja) 2017-12-14
EP3206704A1 (en) 2017-08-23
CN107106638A (zh) 2017-08-29
US20170020956A1 (en) 2017-01-26
CN107580502A (zh) 2018-01-12
WO2016061133A1 (en) 2016-04-21
KR102478073B1 (ko) 2022-12-16
EP3206703A1 (en) 2017-08-23
WO2016061087A1 (en) 2016-04-21
US10016480B2 (en) 2018-07-10
EP3206703B1 (en) 2021-05-19

Similar Documents

Publication Publication Date Title
AU2015333728B2 (en) Peptide-based methods for treating pancreatic cancer
Lee et al. Phosphoinositide 3-kinase signaling mediates β-catenin activation in intestinal epithelial stem and progenitor cells in colitis
Wang et al. Hepatocyte Ninjurin2 promotes hepatic stellate cell activation and liver fibrosis through the IGF1R/EGR1/PDGF-BB signaling pathway
Fu et al. Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies
Jones et al. Trabectedin reduces skeletal prostate cancer tumor size in association with effects on M2 macrophages and efferocytosis
BRPI0710111A2 (pt) proteìna psarc ("sparc") e métodos de uso da mesma
CN114007633A (zh) 作为治疗前列腺癌的新型标志物的ephb4-肝配蛋白b2受体配体对
CN113939309A (zh) 使用sEphB4-HSA融合蛋白治疗癌症
KR20230170695A (ko) 폐암 및 비-소세포 폐암의 치료 방법
EP3836951A1 (en) Peptides and compositions for targeted treatment and imaging
Porcellini et al. The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms
CN114621325A (zh) 一种纤连蛋白靶向多肽及其在促进肿瘤失巢凋亡及化疗增敏中的应用
US9987241B2 (en) Enzyme conjugate and prodrug cancer therapy
TWI359271B (en) Pharmaceutical composition for insulin resistance
US9581598B2 (en) Diagnosis and treatment of brain tumor
KR20200076713A (ko) 암 줄기세포의 저감에 있어서의 wnt5a 펩티드
WO2023002008A1 (en) Thx-b for treating and preventing cancer and metastasis
US20230054634A1 (en) Compositions and methods for treating glioma
US20210060131A1 (en) Intracellular il-1 alpha peptide methods and compositions
JPWO2017086090A1 (ja) 膵癌に特異的な集積性を有するペプチド及びその使用
US20240299505A1 (en) Composition for improving, preventing or treating inflammatory bowel disease comprising nampt-derived peptide as active ingredient
US20240216555A1 (en) Targeting and treatment of cancerous cells using radiolabeled grp78-binding agents
US20250154215A1 (en) Pharmaceutical composition for treating colitis or colorectal cancer comprising colon-targeted s100a8/a9-derived specific peptide
US20240148765A1 (en) Compositions and methods for treating and/or preventing therapy-related cardiomyopathy associated with neutrophil infiltration
WO2024216395A1 (en) APPLICATIONS OF POLYPEPTIDES INHIBITOR OF EAG2 - KVß2 INTERACTION IN CANCER IMMUNOTHERAPY

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired